A Dark Vector Cognition product

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

9K characters. Original on sec.gov ·

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

The 23 tables in Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

EQUITY COMPENSATION PLAN INFORMATION

We currently award stock-based compensation, including stock options and restricted stock units, under the 2020 Equity Incentive Plan. The following table presents information about common stock authorized for issuance under that plan as of June 30, 2026:

Plan CategoryNumber of Securities to be Issued Upon Exercise of Outstanding Options (# in 000’s)Weighted Avg. Exercise Price of Outstanding Options ($)Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A)) (# in 000’s)
(A)(B)(C)
Equity compensation plans approved by shareholders6,991$73.475,876
Equity compensation plans not approved by shareholders-N/A-
Total6,99173.475,876

As of October 9, 2026, there were 5,242,909 shares available for future grants under the 2020 Equity Incentive Plan, and the closing price per share of our common stock was $72.46 as reported on The Nasdaq Global Select Market.

Table of Contents

Principal Shareholders

The following table provides information concerning the only persons known to the Company to be the beneficial owners of more than 5% of the Company’s outstanding common stock as of October 9, 2026.

Name and Address of Beneficial OwnerAmount and Nature of Shares Beneficially OwnedPercent of Class
Vanguard Capital Management
11,559,571(1)7.4%
BlackRock, Inc.
11,011,556(2)7.0%
FMR LLC
12,754,784(3)8.1%
(1)Based solely on information contained in a Schedule 13G, filed with the SEC on April 29, 2026, by Vanguard Capital Management (“VCM”), in which VCM reported that, as of March 31, 2026, it had sole voting power as to 1,379,862 shares of Bio-Techne Common Stock and sole dispositive power as to 11,559,571 shares of Bio-Techne Common Stock. The address of VCM is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355.
(2)Based solely on information contained in a Schedule 13G/A, filed with the SEC on July 16, 2025, by BlackRock, Inc. (“BlackRock”), in which BlackRock reported that, as of June 30, 2025, it had sole voting power as to 10,333,812 shares of Bio-Techne Common Stock and sole dispositive power as to 11,011,556 shares of Bio-Techne Common Stock. The address of BlackRock is 50 Hudson Yards, New York, New York 10001.
(3)Based solely on information contained in a Schedule 13G/A, filed with the SEC on August 6, 2026, by FMR LLC (“FMR”), in which FMR reported that, as of June 30, 2026, it had sole voting power as to 12,715,889.05 shares of Bio-Techne Common Stock and sole dispositive power as to 12,754,783.64 shares of Bio-Techne Common Stock. The address of FMR is 245 Summer Street, Boston, Massachusetts 02210.

Table of Contents

Management Shareholdings

The following table sets forth the number of shares of the Company’s common stock beneficially owned as of October 9, 2026, by each named executive officer, by each director, and by all directors and current executive officers as a group. Each individually beneficially owns less than one percent of total shares outstanding, which includes shares subject to options such individual may exercise. As a group, executive officers and directors beneficially own 1.3% of total shares outstanding.

Name of Director or Executive OfficerNumber of Shares Beneficially Owned(1)% Owned
Robert V. Baumgartner108,265(2)**
Joseph Keegan, Ph.D.66,792(3)**
John L. Higgins128,635(4)**
Alpna Seth, Ph.D.46,700(5)**
Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhil44,628(6)**
Julie L. Bushman33,464(7)**
Dr. Judith Klimovsky12,680(8)**
Dr. Amy Herr20,417(9)**
Kim Kelderman390,300(10)**
James Hippel497,202(11)**
William Geist111,317(12)**
Shane Bohnen53,470(13)**
Steven Crouse85,550(14)**
Matthew McManus7,691(15)**
Officers and directors as a group (13 persons)1,999,708(16)1.3%
*Indicates less than 1.0% ownership of the Company’s shares.
(1)Unless otherwise indicated, the person listed as the beneficial owner has sole voting and sole investment power over outstanding shares. Shares beneficially owned includes shares underlying restricted share awards that are currently outstanding, shares underlying restricted stock units that are currently outstanding and vested or will vest within 60 days of October 9, 2026, shares underlying options that are currently outstanding and exercisable and options that are currently outstanding and will become exercisable within 60 days of October 9, 2026. Percentage ownership calculations are based on 157,055,564 shares issued and outstanding on October 9, 2026.
(2)Includes 56,884 shares held directly and 51,381 shares subject to vested but unexercised share options.
(3)Includes 15,411 shares held directly and 51,381 shares subject to vested but unexercised share options.
(4)Includes 77,254 shares held directly and 51,381 shares subject to vested but unexercised share options.
(5)Includes 15,411 shares held directly and 31,289 shares subject to vested but unexercised share options.
(6)Includes 10,987 shares held directly and 33,641 shares subject to vested but unexercised share options.
(7)Includes 8,775 shares held directly and 24,689 shares subject to vested but unexercised share options.
(8)Includes 3,782 shares held directly and 8,898 shares subject to vested but unexercised share options.
(9)Includes 2,680 shares held directly and 6,192 shares subject to vested but unexercised share options. Additionally, includes 576 shares held by Dr. Herr’s partner and 10,969 shares subject to vested but unexercised share options.
(10)Includes 82,762 shares held directly and 307,538 shares subject to vested but unexercised share options.
(11)Includes 170,183 shares held directly, 315,474 shares subject to vested but unexercised share options and 11,545 restricted stock units that vest within 60 days of October 9, 2026.
(12)Includes 24,943 shares held directly and 86,374 shares subject to vested but unexercised share options.
(13)Includes 10,360 shares held directly and 43,110 shares subject to vested but unexercised share options.
(14)Includes 10,237 shares held directly and 75,313 shares subject to vested but unexercised share options.
(15)Dr. McManus’ employment with the Company terminated effective April 1, 2026. The amount shown is based on his most recent Form 4, filed with the SEC on February 3, 2026.
(16)Includes 400,288 shares of Bio-Techne Common Stock held by Bio-Techne’s Stock Bonus Plan, as to which the Board directs the voting, 489,669 shares held directly, 576 shares held by Dr. Herr’s partner, 1,097,630 shares subject to options that are currently exercisable or will become exercisable within 60 days of October 9, 2026, and 11,545 restricted stock units that vest within 60 days of October 9, 2026.

Table of Contents

Changes in Control

As described above, on June 25, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub, pursuant to which, on the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent. Completion of the Merger will result in a change in control of the Company.

Table of Contents

Previous: Cover and table of contents · Next: Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE